Article
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
The pharmacogenomics journal - 1 Jun 2021
Suenaga Mitsukuni, Schirripa Marta, Cao Shu, Zhang Wu, Cremolini Chiara, Lonardi Sara, Okazaki Satoshi, Berger Martin D, Miyamoto Yuji, Soni Shivani, Barzi Afsaneh, Yamaguchi Toshiharu, Loupakis Fotios, Falcone Alfredo, Lenz Heinz-Josef
Abstract excerpt
Colorectal cancer (CRC) can be classified into subtypes based on gene expression signatures. Patients with stage III enterocyte subtype of the CRC Assigner classifier have been shown to benefit from oxaliplatin adjuvant therapy. Here, we investigated whether single nucleotide polymorphisms (SNPs) in two enterocyte subtype-related genes, MS4A12 and CDX2, could predict the efficacy of oxaliplatin in first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.